<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044130</url>
  </required_header>
  <id_info>
    <org_study_id>01072021</org_study_id>
    <nct_id>NCT05044130</nct_id>
  </id_info>
  <brief_title>Postprandial VLDL-triglyceride Metabolism in Type 2 Diabetes Patients With and Without NAFLD</brief_title>
  <official_title>Postprandial Hepatic Fatty Acid Metabolism During Oral High-fat Mixed-meal Challenge Test in Patients With Type 2 Diabetes With and Without NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Diabetes Academy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from simple reversible hepatic&#xD;
      steatosis to inflammation and fibrosis termed steatohepatitis (NASH). The mechanisms behind&#xD;
      why some subjects progress from NAFLD to NASH are not clear and the responsible mechanism for&#xD;
      storage of excess amounts of liver fat in patients with NAFLD are poorly understood.&#xD;
&#xD;
      Patients with type 2 diabetes mellitus (T2D) and abdominally obese subjects very often have&#xD;
      accumulation of liver fat (NAFLD).&#xD;
&#xD;
      T2D is also associated with abnormal lipid metabolism (dyslipidemia), including free fatty&#xD;
      acids (FFA), hypertriglyceridemia and excessive postprandial hyperlipidemia which increases&#xD;
      the risk of ischemic cardiovascular disease (CVD) and heart failure.&#xD;
&#xD;
      In healthy, insulin sensitive subjects the postprandial increase in triglycerides (TG) is&#xD;
      primarily caused by meal derived chylomicrons, whereas endogenously produced TG (VLDL-TG) and&#xD;
      decreased peripheral TG clearance only becomes quantitatively important in insulin resistant&#xD;
      subjects .Thus, postprandial lipidemia in T2D results from both chylomicronemia as well as a&#xD;
      reduction in both insulin mediated suppression of VLDL-TG secretion and lipoprotein lipase&#xD;
      (LPL) mediated peripheral clearance. A recent study demonstrated that the ability of insulin&#xD;
      to suppress hepatic VLDL-TG after a fat-enriched meal and the duration of the postprandial&#xD;
      hyperlipidemia was similar in patients with T2D compared with age- and BMI matched&#xD;
      individuals without T2D, indicating that the degree of insulin mediated VLDL-TG secretion and&#xD;
      hyperlipidemia primarily depends on insulin sensitivity and not the presence of T2D diabetes&#xD;
      per se.&#xD;
&#xD;
      In these studies, the investigators want to examine the effect of a fat enriched mixed-meal&#xD;
      on hepatic VLDL-TG handling and adipose storage capacity in patients with T2D with and&#xD;
      without NAFLD. Investigators will address these questions using carboxyl-14C triolein labeled&#xD;
      VLDL-TG, magnetic resonance (MR) spectroscopy of liver, muscle and fat biopsies in&#xD;
      combination with state-of-the art muscle and adipose tissue enzyme kinetics, gene- and&#xD;
      protein expression.&#xD;
&#xD;
      The overarching goals are to define abnormalities and differences between patients with T2D&#xD;
      with and without NAFLD in terms of hepatic lipid metabolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 14, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VLDL-triglyceride secretion - Ex vivo labeled VLDL - [14C]-triolein tracer technique.</measure>
    <time_frame>1 day</time_frame>
    <description>(μmol/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VLDL-triglyceride uptake in muscle - Measurement of fatty acid concentration and specific activity in muscle biopsies</measure>
    <time_frame>1 day</time_frame>
    <description>(percent)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VLDL-triglyceride uptake in adipose tissue - Measurement of fatty acid concentration and specific activity in adipose tissue biopsies</measure>
    <time_frame>1 day</time_frame>
    <description>(percent)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VLDL-triglyceride oxidation - Oxidation is measured by specific activity in exhaled air.</measure>
    <time_frame>1 day</time_frame>
    <description>(μmol/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose cell size measurement</measure>
    <time_frame>1 day</time_frame>
    <description>(μl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>1 day</time_frame>
    <description>(mg/kg/min)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>NAFLD</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes with NAFLD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Type 2 Diabetes with NAFLD&#xD;
MR spectroscopy verified steatosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 Diabetes without NAFLD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Type 2 Diabetes without NAFLD&#xD;
MR spectroscopy verified no steatosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High-fat mixed-meal tolerance test (HF-MMTT)</intervention_name>
    <description>The test meal consists of a standardized HF-MMTT (791 cal) with 197 g cream (38 % fat), 18 g sugar and 1 g vanilla sugar for taste (75 g fat, 25 g carbohydrate and 4 g protein)</description>
    <arm_group_label>Type 2 Diabetes with NAFLD</arm_group_label>
    <arm_group_label>Type 2 Diabetes without NAFLD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with Type 2 Diabetes with and without NAFLD (steatosis FF% &gt; 5,6% on MR&#xD;
             spectroscopy for NAFLD and NASH groups)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active smoking&#xD;
&#xD;
          -  Comorbidity other than hypertension and hyperlipidemia&#xD;
&#xD;
          -  Fixed medical drug consumption (including insulin) except statins and anti-diabetic&#xD;
             medications. However, statins must be paused 2 weeks before the examination date and&#xD;
             other antidiabetic medication on examination date.&#xD;
&#xD;
          -  Patients with cancer or former cancer patients&#xD;
&#xD;
          -  Blood donation within the last 3 months prior to the study&#xD;
&#xD;
          -  Participation in experiments involving radioactive isotopes within the last 3 months&#xD;
&#xD;
          -  Alcohol abuse (over 21 items per week for men and over 14 for women)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Indumathi Kumarathas, MD</last_name>
    <phone>+4530299715</phone>
    <email>indumathi@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Endocrinology and Internal Medicine</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 4, 2021</study_first_submitted>
  <study_first_submitted_qc>September 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

